Abstract | OBJECTIVES: METHODS: A comprehensive search was performed in Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase, the Allied and Complementary Medicine Database (AMED), China National Knowledge Infrastructure (CNKI), China Biological Medicine Database (CBM), CQVIP Information and Wanfang Database until January 2013. Only randomized controlled trials (RCTs) evaluating the efficacy and safety of safflower yellow for acute ischemic stroke were included. Two researchers (Fan, S.Y. and Lin, N.) independently extracted data, assessed the study quality, and selected trials for inclusion. RESULTS: 7 RCTs with 762 participants were included. None of the included studies were of high methodological quality. The meta-analysis showed that safflower yellow was more effective assessed by neurological improvement rate [odds ratio (OR), 3.11; 95% confidence interval (CI) 2.06-4.68, P<0.05] compared with control group. No death was reported in any of the included studies during the follow up period. Only four trials reported adverse events, and skin rash was observed in the treatment group of one trial. CONCLUSIONS:
|
Authors | Siyuan Fan, Nan Lin, Guangliang Shan, Pingping Zuo, Liying Cui |
Journal | Complementary therapies in medicine
(Complement Ther Med)
Vol. 22
Issue 2
Pg. 354-61
(Apr 2014)
ISSN: 1873-6963 [Electronic] Scotland |
PMID | 24731908
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- safflower yellow
- Chalcone
|
Topics |
- Chalcone
(analogs & derivatives, therapeutic use)
- Humans
- Randomized Controlled Trials as Topic
- Stroke
(drug therapy)
|